Evaluating outcomes of mother-infant pairs using dolutegravir for HIV treatment during pregnancy
Dolutegravir (DTG), a second-generation integrase inhibitor, is an effective treatment for HIV but its safety and efficacy are not well established in pregnancy. Here, we assess maternal and infant outcomes of mother-infant pairs using DTG-containing regimens during pregnancy. We performed a retrosp...
Gespeichert in:
| Veröffentlicht in: | AIDS (London) 2018-09, Vol.32 (14), p.2017-2021 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2021 |
|---|---|
| container_issue | 14 |
| container_start_page | 2017 |
| container_title | AIDS (London) |
| container_volume | 32 |
| creator | Grayhack, Clara Sheth, Anandi Kirby, Olivia Davis, Jennifer Sibliss, Kedesha Nkwihoreze, Hervette Aaron, Erika Alleyne, Gregg Laguerre, Roberta Rana, Aadia Badell, Martina Momplaisir, Florence |
| description | Dolutegravir (DTG), a second-generation integrase inhibitor, is an effective treatment for HIV but its safety and efficacy are not well established in pregnancy. Here, we assess maternal and infant outcomes of mother-infant pairs using DTG-containing regimens during pregnancy.
We performed a retrospective cohort analysis of pregnant women with HIV on DTG from two urban clinics in the United States, 2015-2018. Maternal outcomes included viral suppression (viral load of |
| doi_str_mv | 10.1097/QAD.0000000000001931 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6125741</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2060873512</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-f46050ef5b153dc4534900fa5d07983b70534d6b5000cd18155f132cbee4102c3</originalsourceid><addsrcrecordid>eNpdkVFLwzAUhYMobk7_gUgffelMmqRpX4Sh0w0GIqivMU2TrdI2NUkH-_dmbI5pXgK53zn3hAPANYJjBHN29zp5HMOjg3KMTsAQEYZjShk6BUOYpHmcYwYH4MK5rwBRmGXnYJDkOSGEJUPwOV2Luhe-apeR6b00jXKR0VFj_ErZuGq1aH3Uicq6qHdbqjR179XSinVlI21sNJt_RN4q4RsV0LK3W6qzatmKVm4uwZkWtVNX-3sE3p-mbw-zePHyPH-YLGJJYOZjTdIQTmlaIIpLSSgmOYRa0BKyPMMFg-GlTAsaPiFLlCFKNcKJLJQiCCYSj8D9zrfri0aVMmSxouadrRphN9yIiv-dtNWKL82apyihjKBgcLs3sOa7V87zpnJS1bVolekdT2AKM4YpSgJKdqi0xjmr9GENgnxbDg_l8P_lBNnNccSD6LcN_AOjM4wH</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2060873512</pqid></control><display><type>article</type><title>Evaluating outcomes of mother-infant pairs using dolutegravir for HIV treatment during pregnancy</title><source>Journals@Ovid Complete</source><source>EZB Electronic Journals Library</source><creator>Grayhack, Clara ; Sheth, Anandi ; Kirby, Olivia ; Davis, Jennifer ; Sibliss, Kedesha ; Nkwihoreze, Hervette ; Aaron, Erika ; Alleyne, Gregg ; Laguerre, Roberta ; Rana, Aadia ; Badell, Martina ; Momplaisir, Florence</creator><creatorcontrib>Grayhack, Clara ; Sheth, Anandi ; Kirby, Olivia ; Davis, Jennifer ; Sibliss, Kedesha ; Nkwihoreze, Hervette ; Aaron, Erika ; Alleyne, Gregg ; Laguerre, Roberta ; Rana, Aadia ; Badell, Martina ; Momplaisir, Florence</creatorcontrib><description>Dolutegravir (DTG), a second-generation integrase inhibitor, is an effective treatment for HIV but its safety and efficacy are not well established in pregnancy. Here, we assess maternal and infant outcomes of mother-infant pairs using DTG-containing regimens during pregnancy.
We performed a retrospective cohort analysis of pregnant women with HIV on DTG from two urban clinics in the United States, 2015-2018. Maternal outcomes included viral suppression (viral load of <20 copies/ml prior to delivery), development of resistance, and tolerability to DTG. Infant outcomes included preterm delivery (birth at <37 weeks), small for gestational age (SGA, weight <10th percentile), infant HIV status at birth, birth defect(s), and Appearance, Pulse, Grimace, Activity, Respiration (APGAR) scores. We performed a trend analysis to assess DTG use over time.
A total of 66 women used DTG during pregnancy and the proportion on DTG increased each year: in 2015, 8% (5/60) of women were on DTG, versus 22% (15/67) in 2016, 42% (30/71) in 2017, and 59% (16/27) in 2018 (P < 0.05). Among women who delivered (n = 57), 77.2% were undetectable at delivery. There were no drug resistance and no reported side effects during pregnancy. Infants had a mean APGAR score of 8 (SD 1.5) at 1 min and 9 (SD 0.8) at 5 min; 31.6% were born prematurely and 15.8% were SGA, and 2 infants had a birth defect. No cases of HIV transmission occurred.
Our findings suggest that DTG can be an effective treatment during pregnancy. Infant outcomes (preterm deliveries and birth defects) need to be investigated in larger studies.</description><identifier>ISSN: 0269-9370</identifier><identifier>EISSN: 1473-5571</identifier><identifier>DOI: 10.1097/QAD.0000000000001931</identifier><identifier>PMID: 29944472</identifier><language>eng</language><publisher>England: Lippincott Williams & Wilkins</publisher><subject>AIDS/HIV ; Clinical Science: Concise Communication</subject><ispartof>AIDS (London), 2018-09, Vol.32 (14), p.2017-2021</ispartof><rights>Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-f46050ef5b153dc4534900fa5d07983b70534d6b5000cd18155f132cbee4102c3</citedby><cites>FETCH-LOGICAL-c408t-f46050ef5b153dc4534900fa5d07983b70534d6b5000cd18155f132cbee4102c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,781,785,886,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29944472$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grayhack, Clara</creatorcontrib><creatorcontrib>Sheth, Anandi</creatorcontrib><creatorcontrib>Kirby, Olivia</creatorcontrib><creatorcontrib>Davis, Jennifer</creatorcontrib><creatorcontrib>Sibliss, Kedesha</creatorcontrib><creatorcontrib>Nkwihoreze, Hervette</creatorcontrib><creatorcontrib>Aaron, Erika</creatorcontrib><creatorcontrib>Alleyne, Gregg</creatorcontrib><creatorcontrib>Laguerre, Roberta</creatorcontrib><creatorcontrib>Rana, Aadia</creatorcontrib><creatorcontrib>Badell, Martina</creatorcontrib><creatorcontrib>Momplaisir, Florence</creatorcontrib><title>Evaluating outcomes of mother-infant pairs using dolutegravir for HIV treatment during pregnancy</title><title>AIDS (London)</title><addtitle>AIDS</addtitle><description>Dolutegravir (DTG), a second-generation integrase inhibitor, is an effective treatment for HIV but its safety and efficacy are not well established in pregnancy. Here, we assess maternal and infant outcomes of mother-infant pairs using DTG-containing regimens during pregnancy.
We performed a retrospective cohort analysis of pregnant women with HIV on DTG from two urban clinics in the United States, 2015-2018. Maternal outcomes included viral suppression (viral load of <20 copies/ml prior to delivery), development of resistance, and tolerability to DTG. Infant outcomes included preterm delivery (birth at <37 weeks), small for gestational age (SGA, weight <10th percentile), infant HIV status at birth, birth defect(s), and Appearance, Pulse, Grimace, Activity, Respiration (APGAR) scores. We performed a trend analysis to assess DTG use over time.
A total of 66 women used DTG during pregnancy and the proportion on DTG increased each year: in 2015, 8% (5/60) of women were on DTG, versus 22% (15/67) in 2016, 42% (30/71) in 2017, and 59% (16/27) in 2018 (P < 0.05). Among women who delivered (n = 57), 77.2% were undetectable at delivery. There were no drug resistance and no reported side effects during pregnancy. Infants had a mean APGAR score of 8 (SD 1.5) at 1 min and 9 (SD 0.8) at 5 min; 31.6% were born prematurely and 15.8% were SGA, and 2 infants had a birth defect. No cases of HIV transmission occurred.
Our findings suggest that DTG can be an effective treatment during pregnancy. Infant outcomes (preterm deliveries and birth defects) need to be investigated in larger studies.</description><subject>AIDS/HIV</subject><subject>Clinical Science: Concise Communication</subject><issn>0269-9370</issn><issn>1473-5571</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpdkVFLwzAUhYMobk7_gUgffelMmqRpX4Sh0w0GIqivMU2TrdI2NUkH-_dmbI5pXgK53zn3hAPANYJjBHN29zp5HMOjg3KMTsAQEYZjShk6BUOYpHmcYwYH4MK5rwBRmGXnYJDkOSGEJUPwOV2Luhe-apeR6b00jXKR0VFj_ErZuGq1aH3Uicq6qHdbqjR179XSinVlI21sNJt_RN4q4RsV0LK3W6qzatmKVm4uwZkWtVNX-3sE3p-mbw-zePHyPH-YLGJJYOZjTdIQTmlaIIpLSSgmOYRa0BKyPMMFg-GlTAsaPiFLlCFKNcKJLJQiCCYSj8D9zrfri0aVMmSxouadrRphN9yIiv-dtNWKL82apyihjKBgcLs3sOa7V87zpnJS1bVolekdT2AKM4YpSgJKdqi0xjmr9GENgnxbDg_l8P_lBNnNccSD6LcN_AOjM4wH</recordid><startdate>20180910</startdate><enddate>20180910</enddate><creator>Grayhack, Clara</creator><creator>Sheth, Anandi</creator><creator>Kirby, Olivia</creator><creator>Davis, Jennifer</creator><creator>Sibliss, Kedesha</creator><creator>Nkwihoreze, Hervette</creator><creator>Aaron, Erika</creator><creator>Alleyne, Gregg</creator><creator>Laguerre, Roberta</creator><creator>Rana, Aadia</creator><creator>Badell, Martina</creator><creator>Momplaisir, Florence</creator><general>Lippincott Williams & Wilkins</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180910</creationdate><title>Evaluating outcomes of mother-infant pairs using dolutegravir for HIV treatment during pregnancy</title><author>Grayhack, Clara ; Sheth, Anandi ; Kirby, Olivia ; Davis, Jennifer ; Sibliss, Kedesha ; Nkwihoreze, Hervette ; Aaron, Erika ; Alleyne, Gregg ; Laguerre, Roberta ; Rana, Aadia ; Badell, Martina ; Momplaisir, Florence</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-f46050ef5b153dc4534900fa5d07983b70534d6b5000cd18155f132cbee4102c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>AIDS/HIV</topic><topic>Clinical Science: Concise Communication</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grayhack, Clara</creatorcontrib><creatorcontrib>Sheth, Anandi</creatorcontrib><creatorcontrib>Kirby, Olivia</creatorcontrib><creatorcontrib>Davis, Jennifer</creatorcontrib><creatorcontrib>Sibliss, Kedesha</creatorcontrib><creatorcontrib>Nkwihoreze, Hervette</creatorcontrib><creatorcontrib>Aaron, Erika</creatorcontrib><creatorcontrib>Alleyne, Gregg</creatorcontrib><creatorcontrib>Laguerre, Roberta</creatorcontrib><creatorcontrib>Rana, Aadia</creatorcontrib><creatorcontrib>Badell, Martina</creatorcontrib><creatorcontrib>Momplaisir, Florence</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>AIDS (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grayhack, Clara</au><au>Sheth, Anandi</au><au>Kirby, Olivia</au><au>Davis, Jennifer</au><au>Sibliss, Kedesha</au><au>Nkwihoreze, Hervette</au><au>Aaron, Erika</au><au>Alleyne, Gregg</au><au>Laguerre, Roberta</au><au>Rana, Aadia</au><au>Badell, Martina</au><au>Momplaisir, Florence</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluating outcomes of mother-infant pairs using dolutegravir for HIV treatment during pregnancy</atitle><jtitle>AIDS (London)</jtitle><addtitle>AIDS</addtitle><date>2018-09-10</date><risdate>2018</risdate><volume>32</volume><issue>14</issue><spage>2017</spage><epage>2021</epage><pages>2017-2021</pages><issn>0269-9370</issn><eissn>1473-5571</eissn><abstract>Dolutegravir (DTG), a second-generation integrase inhibitor, is an effective treatment for HIV but its safety and efficacy are not well established in pregnancy. Here, we assess maternal and infant outcomes of mother-infant pairs using DTG-containing regimens during pregnancy.
We performed a retrospective cohort analysis of pregnant women with HIV on DTG from two urban clinics in the United States, 2015-2018. Maternal outcomes included viral suppression (viral load of <20 copies/ml prior to delivery), development of resistance, and tolerability to DTG. Infant outcomes included preterm delivery (birth at <37 weeks), small for gestational age (SGA, weight <10th percentile), infant HIV status at birth, birth defect(s), and Appearance, Pulse, Grimace, Activity, Respiration (APGAR) scores. We performed a trend analysis to assess DTG use over time.
A total of 66 women used DTG during pregnancy and the proportion on DTG increased each year: in 2015, 8% (5/60) of women were on DTG, versus 22% (15/67) in 2016, 42% (30/71) in 2017, and 59% (16/27) in 2018 (P < 0.05). Among women who delivered (n = 57), 77.2% were undetectable at delivery. There were no drug resistance and no reported side effects during pregnancy. Infants had a mean APGAR score of 8 (SD 1.5) at 1 min and 9 (SD 0.8) at 5 min; 31.6% were born prematurely and 15.8% were SGA, and 2 infants had a birth defect. No cases of HIV transmission occurred.
Our findings suggest that DTG can be an effective treatment during pregnancy. Infant outcomes (preterm deliveries and birth defects) need to be investigated in larger studies.</abstract><cop>England</cop><pub>Lippincott Williams & Wilkins</pub><pmid>29944472</pmid><doi>10.1097/QAD.0000000000001931</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-9370 |
| ispartof | AIDS (London), 2018-09, Vol.32 (14), p.2017-2021 |
| issn | 0269-9370 1473-5571 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6125741 |
| source | Journals@Ovid Complete; EZB Electronic Journals Library |
| subjects | AIDS/HIV Clinical Science: Concise Communication |
| title | Evaluating outcomes of mother-infant pairs using dolutegravir for HIV treatment during pregnancy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T15%3A19%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluating%20outcomes%20of%20mother-infant%20pairs%20using%20dolutegravir%20for%20HIV%20treatment%20during%20pregnancy&rft.jtitle=AIDS%20(London)&rft.au=Grayhack,%20Clara&rft.date=2018-09-10&rft.volume=32&rft.issue=14&rft.spage=2017&rft.epage=2021&rft.pages=2017-2021&rft.issn=0269-9370&rft.eissn=1473-5571&rft_id=info:doi/10.1097/QAD.0000000000001931&rft_dat=%3Cproquest_pubme%3E2060873512%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2060873512&rft_id=info:pmid/29944472&rfr_iscdi=true |